Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05383196 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Onvansertib + Paclitaxel In TNBC

StatusActive, Not Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Feb 15, 2026 to Dec 15, 2026v10
  2. Re-verified, no change to tracked fieldsv9
  3. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 3 of 3 sites
    v8
  4. Site contacts updated at 3 of 3 sitesv7
  5. 3 versions Re-verified since May 22, 2023, no change to tracked fieldsv4-v6
Show 2 earlier versionsHide 2 earlier versions
  1. Study title shortened, about 2 wordsv3
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Sep 2022 to Sep 30, 2022
    • Site details revised at 3 of 3 sites
    • Study title shortened, about 5 words
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This research is being done to evaluate the safety and effectiveness of Onvansertib in combination with Paclitaxel in triple-negative breast cancer (TNBC) that has spread to other parts of the body. The names of the study interventions involved in this study are: * Onvansertib * Paclitaxel
Trial Details
NCT Number NCT05383196
Lead Sponsor Antonio Giordano, MD
Collaborators: Cardiff Oncology
Conditions
(from sponsor)		 Breast Cancer, Invasive Breast Cancer, Unresectable Breast Carcinoma, Locally Advanced Breast Cancer, Metastatic Breast Cancer, Inflammatory Breast Cancer, Triple Negative Breast Cancer (TNBC), Hormone Receptor/Growth Factor Receptor-Negative Breast Cancer +2 more
Related terms Breast Neoplasms, Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov